The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.本發明提供特異性結合表皮生長因子受體變異體III(EGFRvIII)之嵌合型抗原受體(CAR)。本發明進一步關於包含該等CAR之經工程處理之免疫細胞、編碼CAR之核酸及製造該等CAR、經工程處理之免疫細胞和核酸之方法。本發明進一步關於使用該等CAR和經工程處理之免疫細胞以治療由EGFRvIII介導之病狀之治療方法,該等病狀包括癌症(諸如膠質母細胞瘤)。